Clinical Trial Update: Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating nivolumab in Epstein-Barr virus–positive lymphoproliferative disorders and EBV-positive non-Hodgkin lymphomas; currently recru…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epstein-barr Virus Infection
• Lymphoma
• Lymphoproliferative Disorder
• Non-hodgkin Lymphoma

Drugs mentioned

• OPDIVO (nivolumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Epstein-Barr Virus Infections, Lymphoma | Phase 2 | Status: RECRUITING